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Abstract:
PURPOSE: The purpose of this study was to review the clinical presentation, systemic work‑up, and outcomes
of all previously reported ocular adnexal (OA) metastases from renal cell carcinoma (RCC).
METHODS: This was a literature review. PubMed and Google Scholar databases were searched for all
well‑documented cases of OA metastases from RCC.
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RESULTS: Final analysis identified 44 patients with either biopsy‑confirmed (41/44, 93%) or treatment
response‑documented (3/44, 6%) OA metastases from RCC. Thirty‑four (77%) patients were male. The median
age was 60 years (mean: 60, range: 22–87 years). The most common presenting signs were proptosis (19/44, 43%)
and OA mass (14/44, 32%). Metastases most frequently involved the orbital bones (10/44, 23%) and adjacent
extraconal fat, extending from the sinonasal tract in 7/10 (70%) of these cases. OA metastases were initial
manifestation of RCC in 18/44 (41%) patients. At the time of primary tumor diagnosis, 22 of 30 (73%) patients
had American Joint Committee on Cancer Stage IV disease with metastases to 2 or more sites in 13 (57%)
patients. Seventeen of 42 (40%) patients underwent local therapy only, which most commonly included excision/
exenteration with margin control (10/17, 59%). Twenty‑five of 42 (60%) patients had systemic therapy, which
included biologic agents and chemotherapy. The absolute 5‑year survival rate was 66% with significantly
improved survival in patients reported after 2006 (92% vs. 42%, P = 0.04) and in those with isolated OA
metastases (100% vs. 27%, P = 0.02) at 30 months.
CONCLUSION: Although RCC metastases to OA occur in a setting of advanced disease, the recent advances
in diagnostic modalities and targeted therapies resulted in improved survival.
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Introduction

R

enal cell carcinoma (RCC) is one of the
most common cancers affecting both sexes
in the United States.[1] According to the Review
of the Surveillance, Epidemiology, and End
Results (SEER) cancer registry, the overall
incidence and mortality rates of RCC in the
United States have steadily increased between
1992 and 2015.[2] The rise in RCC incidence has
been attributed to an increase in the prevalence
of RCC risk factors, such as smoking, obesity,
and hypertension,[3,4] and to the higher rate
of incidental detection of RCC driven by the
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increasing availability of the imaging studies.
In recent years, however, the incidence rates
of RCC have stabilized, and the mortality rates
have decreased.[2] It is speculated that this decline
in mortality is related to earlier detection and
improved therapies for metastatic RCC.[2]
Approximately one‑third of patients with
RCC have metastatic disease at the time of
diagnosis, with lung, bones, liver, and brain
being the most commonly affected.[5,6] Ocular
adnexal (OA) and intraocular involvement by
RCC is infrequent.[7] To our knowledge, the most
recent largest published systematic review by
Shome et al. in 2008 included 33 patients with
OA RCC metastases.[8] In light of changes in the
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epidemiology and treatment approaches to RCC over the last
15 years,[9‑11] herein, we provide an updated comprehensive
review of the published literature on the RCC metastatic
to the OA to characterize its clinical presentation, systemic
manifestations, diagnosis, and management.

Institutional review board approval was waived for this
literature review. This study adhered to the ethical principles
outlined in the Declaration of Helsinki as amended in 2013
and was Health Insurance Portability and Accountability Act
of 1996 (HIPAA) compliant.

Literature search

A comprehensive review of the literature was performed
with a systematic search of the PubMed and Google Scholar
databases for all articles published between January 1957
and January 2021 using the following key terms: “renal
cell carcinoma ocular adnexal metastases” or “renal cell
carcinoma orbital metastases” or “orbital metastases kidney”
or “renal cell carcinoma sinonasal metastases” or “renal cell
carcinoma lacrimal gland metastases” or “renal cell carcinoma
ocular muscle metastases” or “renal cell carcinoma eyelid”
or “renal cell carcinoma conjunctival metastases” or “renal
cell carcinoma eye” or “renal cell carcinoma ocular adnexa”
or “renal cell carcinoma orbit” or “renal cell carcinoma
sinonasal” or “renal cell carcinoma lacrimal gland” or “renal
cell carcinoma ocular muscle” or “renal cell carcinoma eyelid”
or “renal cell carcinoma conjunctiva.” Additional articles were
found by reference searching. Duplicates were removed. All
articles published in all languages that met the eligibility
criteria were selected for further analysis.

Eligibility criteria

To be included for detailed analysis, only peer‑reviewed
case studies and case series were included that documented
OA (conjunctiva, eyelid, orbital fat, extraocular muscle, lacrimal
gland, and orbital bone) biopsy‑confirmed metastases from RCC.
If an OA biopsy was not performed, documentation of response to
systemic therapy for metastatic RCC was required for inclusion
in this study. Isolated intraocular RCC metastases were excluded.

Data collection

All articles that met the inclusion criteria were reviewed for the
following data: patient demographics (age at diagnosis of OA
metastases, sex, and ethnicity), presenting ocular symptoms, eye
laterality, duration of symptoms, distribution of OA involvement
by metastasis, history of RCC, histopathological type of RCC,
presence of other synchronous metastases, American Joint
Committee on Cancer (AJCC) tumor‑node‑metastasis system
staging at the time of RCC diagnosis,[12] diagnostic modalities,
management of OA and systemic disease, ophthalmic and
systemic outcomes, and follow‑up period.
All analysis was performed using RStudio Desktop
1.2.5033 (RStudio Inc., Boston, MA, USA). Significance
210

Results
Patient demographics and presenting features

Methods

Statistical analysis

testing was performed on Kaplan–Meier survival distributions
using the log‑rank test. P ≤ 0.05 was considered statistically
significant.

Review of the literature identified 44 patients[8,13‑51] who met
the inclusion criteria for this study. Table 1 summarizes the
demographics and presenting characteristics. Patients with
OA metastases from RCC presented at an average age of
60 years (median: 60, range: 22–87). Thirty‑four (77%)
Table 1: Ocular adnexal metastases from renal cell
carcinoma: Demographics and presenting characteristics
Variables

n (%)

Age (years)
Mean
60
Median
60
Range
22‑87
Sex
Male
34/44 (77)
Female
10/44 (23)
Ethnicity
Caucasian
8/12 (67)
African American
1/12 (8)
Hispanic
1/12 (8)
Asian
1/12 (8)
Other
1/12 (8)
Presenting ocular symptoms
Proptosis
19/44 (43)
Mass
14/44 (32)
Diplopia
12/44 (27)
Pain/discomfort
8/44 (18)
Vision change
8/44 (18)
Swelling/chemosis
4/44 (9)
Other*
16/44 (36)
Laterality
Right eye
22/44 (50)
Left eye
19/44 (43)
Bilateral
3/44 (7)
Tissue primarily involved
Conjunctiva
8/44 (18)
Orbital space not otherwise specified
7/44 (16)
Muscle
6/44 (14)
Orbital bone†
10/44 (23)
Intraconal orbital fat
3/44 (7)
Extraconal orbital fat
3/44 (7)
Lacrimal gland
1/44 (2)
OA focality
Unifocal
33/40 (83)
Multifocal
7/40 (18)
History of RCC at the time of diagnosis
Yes
26/44 (59)
No
18/44 (41)
*Epistaxis, nasal obstruction/congestion, redness, photophobia, epiphora,
ptosis, headache, †In 7 patients, orbital involvement occurred as a result of
extension from the sinonasal tract. RCC: Renal cell carcinoma, OA: Ocular
adnexal
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patients were male. Of the 12 patients with documented
ethnicity, most were Caucasian (8/12, 67%). The most common
presenting ocular symptoms were proptosis (19/44, 43%),
an OA mass (14/44, 32%), and diplopia (12/44, 27%). The
average duration of ocular symptoms was 3 months (median:
3, range: 0.3–8). In most patients, the OA metastases were
unilateral (41/44, 93%) and unifocal (33/40, 83%). Most OA
metastases were centered in the orbital bone with extension
into the adjacent orbital fat, accounting for 10 of 44 (23%)
cases. Bony orbital involvement generally occurred as a
result of extension of metastasis from the sinonasal tract in
7 of these 10 (70%) patients. Other frequently involved OA
tissues were conjunctiva (8/44, 18%), muscle (6/44, 14%),
intraconal orbital fat (3/44, 7%), extraconal orbital fat (3/44,
7%), lacrimal gland (1/44, 2%), or orbital space not otherwise
specified (7/44, 16%).

Imaging

The detailed information on diagnostic work‑up is documented
in Table 2. Orbital imaging was performed in 34 of
44 (77%) patients. The most common diagnostic study for
evaluation of orbital disease was computed tomography (CT)
scan (17/34, 50%). Multimodal imaging was performed in
10 of 34 (29%) patients, which included a combination of
plain X‑ray, ultrasound, CT/CT angiography (CTA), and
magnetic resonance imaging (MRI). CT of the abdomen was

Pathologic diagnosis and histopathologic characteristics
of renal cell carcinoma

OA biopsy documenting metastatic RCC was performed in
41 of 44 (93%) patients, which was incisional in 26/41 (63%)
and excisional in 15/41 (37%) [Table 2]. Three of 41 (7%)
patients were empirically diagnosed with metastatic OA RCC
based on clinical and imaging findings and had a documented
response to systemic therapy for metastatic RCC. Ancillary
immunohistochemical studies on tissue were performed
in 18/25 (72%) cases and included cytokeratins (6/25,
24%), CD10 (8/25, 32%), vimentin (7/25, 28%), epithelial
membrane antigen (EMA) (3/25, 12%), carbonic anhydrase
IX (CAIX) (2/25, 8%), paired‑box gene 8 (PAX8) (2/25,
8%), and RCC antigen (RCC) (1/25, 4%). In 14 patients
with documented pathology data on primary RCC, the
diagnosis was established by incisional biopsy in 5/14 (36%)
and by nephrectomy in 9/14 (64%). Of 22 patients with
available information, the most common RCC type was
clear cell (18/22, 82%), followed by papillary (2/22, 9%) and
medullary (2/22, 9%) [Table 3].

Systemic disease characteristics

Table 3 summarizes the systemic characteristics of RCC.
The AJCC 8th edition staging system for kidney tumors

Table 2: Ocular adnexal metastases from renal cell
carcinoma: Diagnostic work‑up
Variables

the most common systemic imaging study performed (15/24,
63%) followed by multimodal imaging (5/24, 21%), which
included a combination of plain X‑ray/pyelogram, ultrasound,
CT/CTA, or MRI.

n (%)

OA metastasis work‑up
OA biopsy
Incisional/fine‑needle aspiration*
26/41 (63)
Excisional
15/41 (37)
Ancillary studies on biopsied tissue
Immunohistochemical stains**
18/25 (72)
None
7/25 (28)
Orbital imaging
CT
17/34 (50)
Multimodal†
10/34 (29)
MRI
3/34 (9)
X‑ray
2/34 (6)
Ultrasound
2/34 (6)
Systemic work‑up
RCC biopsy, primary site
Incisional biopsy
5/14 (36)
Nephrectomy
9/14 (64)
Systemic imaging
CT
15/24 (63)
Multimodal‡
5/24 (21)
Other§
3/24 (13)
MRI
1/24 (4)
*Immunohistochemical stains including positive for any of the
following: CD10, vimentin, cytokeratin (CK7/18/20), CAM 5.2,
AE1/AE3, EMA, Ki67, CAIX, PAX8, CD34, CD68, bh11, CEA,
anti‑AFP, smarcb1/ini1, cyclin D1, RCC antigen, †Combination of
imaging with plain X‑ray, CT/CT angiogram, MRI or ultrasound,
‡
Combination of imaging with CT/CT angiogram, MRI or ultrasound,
§
Pyelogram. RCC: Renal cell carcinoma, OA: Ocular adnexal, CT:
Computed tomography, MRI: Magnetic resonance imaging, CEA:
Carcinoembryonic antigen, AFP: Alpha‑fetoprotein, EMA: Epithelial
membrane antigen, CAIX: Carbonic anhydrase IX, PAX8: Paired‑box
gene 8, CK8: cytokeratin 8

Table 3: Ocular adnexal metastases from renal cell
carcinoma: Systemic disease characteristics
Variable
Type of renal cell carcinoma
Clear cell
Papillary
Medullary
AJCC staging at the time of primary tumor diagnosis*
Stage I (T1, N0, M0)
Stage II (T2, N0, M0)
Stage III (T1/T2/T3, N1, M0) or (T3, N0, M0)
Stage IV (T4, any N, M0) or (any T, any N, M1)
Time (months) to ocular metastases from diagnosis or
nephrectomy of RCC
Mean, median, range

n (%)
18/22 (82)
2/22 (9)
2/22 (9)
3/30 (10)
2/30 (7)
3/30 (10)
22/30 (73)

79.5 (78,
1‑180)

Other synchronous metastases sites
Multifocal†
13/23 (57)
Lung
5/23 (22)
Adrenal gland
1/23 (4)
Vertebrae
1/23 (4)
Pelvic bones
1/23 (4)
Mediastinum
1/23 (4)
Other‡
1/23 (4)
*RCC TNM staging, AJCC 8th edition.[12] †Two or more sites from
brain, adrenal gland, lung, vertebrae, pelvic bones, mediastinum, liver,
skin, breast, diaphragm, oral cavity, ‡Perihilar region. RCC: Renal
cell carcinoma, AJCC: American Joint Committee on Cancer,
TNM: Tumor‑node‑metastasis
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Figure 1: Overall survival analysis using Kaplan–Meier curve. Dotted lines
represent 95% confidence intervals. Final death occurred at the last follow‑up
point at 23 months (n = 27). Overall, the 5‑year survival rate is 66%

was used to record the stage at the time of diagnosis of the
primary tumor.[12] Most patients (22/30, 73%) had Stage
IV (any T, any N, M1) disease at the time of diagnosis,
presenting with distant metastasis [Table 3]. OA metastases
presented following detection of primary RCC in 26/44 (59%)
and were initial manifestation of RCC in 18/44 (41%)
patients [Table 1]. The average time from diagnosis of primary
RCC to OA metastases was 80 months (median: 78, range:
1–180) [Table 3]. OA was the only metastatic site in 8 of
31 (26%) patients who had documented systemic evaluation
data. Concurrent extra‑OA metastases were identified in 23 on
31 (74%) patients, which most commonly involved lung (5/23,
22%) and were multifocal (two or more sites) in 13/23 (57%)
patients [Table 3].

Management

Table 4 summarizes the management and outcomes of
patients with OA metastasis from RCC. Information on
management of OA RCC metastases was available on
42 of 44 (95%) patients. Of patients with OA metastases
who underwent local therapy only (17/42, 40%), the most
common intervention was resection with margin control
in 10/17 (59%) patients and biopsy or resection followed
by radiotherapy to the orbit in 6/17 (35%) patients. Two
patients with a locally advanced disease involving sinuses
and skull base underwent orbital exenteration, either
as a monotherapy (reported in 2012)[38] or followed by
radiotherapy (reported in 1957).[13] Twenty‑five of 42 (60%)
patients had systemic treatment in addition to any local OA
therapy, which included biologic agents only (11/42, 26%),
chemotherapy only (3/42, 7%), radiotherapy only (1/42,
2%), surgical resection of extra‑OA metastases (1/42, 2%),
palliative therapy (1/42, 2%), and combination therapy
212

Figure 2: Kaplan–Meier curve stratified by study date, between 1990
and 2005 versus 2006 and 2020. Dotted lines represent 95% confidence
intervals. The 5‑year survival rate at the 30‑month mark from 1990
to 2005 was 42% and from 2006 to 2020 was 92%. A log‑rank test
comparing the two survival curves revealed a test statistic of 4.2 (degree
of freedom: 1), P = 0.04 (n = 22)

in 8 out of 42 (19%). The combination therapy included
radiotherapy with surgery (2/8, 25%), chemotherapy with
biologic agents (2/8, 25%), radiotherapy with biologic
agents (2/8, 25%), chemotherapy with radiotherapy
and biologic agents (1/8, 13%), and chemotherapy with
radiosurgery (1/8, 13%). Treatment of primary RCC
included nephrectomy in 30/33 (91%) with neoadjuvant
biologic agents in 2/33 (6%) and surgery with radiotherapy
in 1/33 (3%). Two patients (2/33, 6%) refused treatment.
Biologic agents used included receptor protein‑tyrosine
kinase inhibitors (sunitinib, sorafenib, and pazopanib) and
immunomodulatory agents (immune checkpoint inhibitors,
interferon‑alpha, and interleukin‑2).

Outcome

The average follow‑up was 18 months (median: 12, range:
0.3–72 months) [Table 4]. Of the 37 patients with available
follow‑up, 10/37 (27%) were alive with no evidence
of disease, 18/37 (49%) alive with disease, 8/37 (22%)
deceased due to disease, and 1/37 (3%) deceased due to
another cause. The overall 5‑year Kaplan–Meier survival
rate for 27 patients with available information was
66% [Figure 1]. A subgroup analysis of 22 patients with
complete information on OA RCC metastasis reported
between 2006 and 2020 (15/22, 68%) demonstrated a
significantly improved survival at 30‑month mark when
compared to those reported between 1990 and 2005 (92%
vs. 42% vs. P =0.04) [Figure 2]. In addition, in a subgroup
analysis of 21 patients with complete information, patients
who presented with metastases to OA only (8/21, 38%)
versus those who had metastases to additional sites (13/21,
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Figure 3: Kaplan–Meier curve: isolated ocular adnexal metastases
versus additional metastases to other sites. Dotted lines represent 95%
confidence intervals. The survival rate at the 30‑month mark was 100%
in patients who presented with metastases to OA only versus 27% in
patients with metastases to additional sites. A log‑rank test comparing
the two survival curves revealed a test statistic of 5.9 (degree of freedom:
1), P = 0.02 (n = 21)

62%) showed an improved survival at the 30‑month
mark (100% vs. 27%, P = 0.02) [Figure 3].

Discussion
Orbital metastases are uncommon, with the incidence ranging
between 1% and 13%.[52‑54] RCC accounts for 5%–11% of
orbital metastases.[53,55] In this review of 44 patients, OA
metastases from RCC were more common in males (77%),
with an average age of 60 years. These demographic data are
similar to the distribution of RCC in general population[56] and
are concurrent with the previously published studies on OA
metastases from RCC.[8]
OA metastases from RCC present with symptoms related to
mass effect, such as proptosis, mass, swelling, and diplopia.
Notably, RCC is the most common malignant tumor that
metastasizes to the nasal cavity and paranasal sinus[57] and can
extend into the orbit from the sinonasal tract, presenting with
symptoms of nasal obstruction and epistaxis. It is, therefore,
crucial that detailed eye examination is performed along with
thorough review of symptoms.
Orbital imaging plays a valuable role in the diagnostic
work‑up of OA metastases. The most common imaging
modality is CT scan, performed in up to 80% of cases as a
single imaging modality or in combination with other imaging
studies [Figure 4]. However, definitive diagnosis requires
tissue biopsy. In this review, clear cell RCC accounted for
82% of all RCC metastases, which is in keeping with the
overall frequency of clear cell RCC [Figure 5a].[58] Ancillary

a

b

c

d

e

f

Figure 4: Renal cell carcinoma metastases to the ocular adnexa: clinical
findings and imaging studies in a  67‑year‑old male with an 8‑month
history of slowly progressive left exophthalmos. There was no history of
renal cell carcinoma. (a) Left exophthalmos and hypoglobus. (b) Axial
and (c) coronal computed tomography (soft‑tissue window) shows a
left superior orbital mass extending into the frontal sinus and anterior
cranial fossa. (d) Coronal computed tomography (bone window) with
obvious bone erosion along the skull base. (e) Axial and (f) coronal
magnetic resonance imaging, T1‑weighted image with contrast and fat
suppression. Note the inferior displacement of the left globe by the mass
on the coronal image

immunohistochemical studies are frequently performed to
support the morphologic diagnosis. Clear cell RCC expresses
PAX8, CD10, CAIX, RCC, epithelial markers (cytokeratins
AE1/AE3 and CAM5.2 and EMA), and vimentin [Figure 5b‑d].
Thus, this immunohistochemical panel is frequently used in
evaluation of suspected metastatic RCC.[42,59,60]
OA involvement by RCC occurs on average 6–7 years
following the diagnosis of primary tumor in 59% of patients.
However, metastases as late as 15 years following the diagnosis
of primary RCC can occur, highlighting the importance of
careful medical and surgical history.[16,19,39] Importantly, our
review demonstrated that OA RCC can also occur as an
initial manifestation of metastatic disease in 41% of patients.
Thus, RCC should be an important consideration in a patient
with orbital metastasis from an unknown primary, prompting
appropriate systemic evaluation. Systemic imaging such as CT,
positron emission tomography/CT, MRI, and ultrasound are
useful screening modalities for RCC with multimodal imaging
employed in 21% of patients in this review.
Approximately 15%–30% of patients with RCC have
metastases at the time of diagnosis[56,61,62] and 20%–50% will
progress to metastatic cancer,[63] with distant metastases most
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commonly involving the lungs, liver, and bone.[5] Interestingly,
in this review, 73% of patients with OA metastases had Stage
IV metastatic disease at the time of primary tumor diagnosis.
Thus, most OA metastases from RCC occur either in a
setting of previously known metastatic disease or as an initial
manifestation of RCC.
a

b

c

d

Figure 5: Renal cell carcinoma metastases to the ocular adnexa: pathology.
Biopsy of the mass documented in Figure 4 demonstrates (a) nests and sheets of
cells with clear cytoplasm and distinct cell membranes separated by capillaries,
characteristic of clear cell renal cell carcinoma. Immunohistochemical
studies show that the neoplastic cells demonstrate membranous staining
for carbonic anhydrase IX (b), cytoplasmic and membranous staining for
renal cell carcinoma antigen (c), and nuclear staining for paired‑box gene
8 (d) supporting the diagnosis of clear cell renal cell carcinoma. (stains: h and
E [a], carbonic anhydrase IX [b], renal cell carcinoma [c], paired‑box gene
8 [d]; original magnification × 400 [a], 250 [b‑d])

Table 4: Ocular adnexal metastases from renal cell
carcinoma: Management and outcomes
Variables
OA metastases local intervention only
Excision/exenteration with margin control only
Biopsy or excision followed by regional radiotherapy
Other*
RCC primary treatment
Nephrectomy
Other*
Surgery + radiotherapy
Systemic treatment
No treatment
Biologic agents only†
Combination‡
Chemotherapy only
Palliative only
Surgical resection of extra‑OA metastases
Radiotherapy only
Time (months) from diagnosis of OA metastases to
final follow up
Mean, median, range

n (%)
10/17 (59)
6/17 (35)
1/17 (6)
30/33 (91)
2/33 (6)
1/3 (33)
17/42 (40)
11/42 (26)
8/42 (19)
3/42 (7)
1/42 (2)
1/42 (2)
1/42 (2)

Survival for RCC is highly dependent on the stage at
diagnosis, with only 10%–12% 5‑year survival for Stage
IV metastatic disease documented in prior studies.[63,64]
However, the recent SEER database review found that
mortality rate for metastatic RCC decreased significantly
since 2012. [2] This improvement in survival has been
attributed to the more rigorous imaging guidelines to detect
RCC and the use of novel immunotherapy and targeted
therapy agents. In our review for OA RCC metastases,
we found that the absolute 5‑year survival rate was 66%.
Patients with isolated OA RCC metastases had improved
survival when compared to those with additional metastases
to other sites. In line with the observations from SEER
database, [2] we noted a significantly improved 5‑year
survival in patients who had OA RCC metastases reported
in the last 15 years (2006–2020).

Limitations

The inherent limitations of this study are the small sample
size, which reflects rarity of RCC metastases to OA and
heterogeneity in pathology reporting, diagnostic studies,
oncologic staging, and therapeutic options, which reflects the
evolution in our diagnostic approach, risk stratification, and
management of RCC over the course of 5 decades.

Conclusion

18 (12,
0.3‑72)

Outcome
Alive with no evidence of disease
10/37 (27)
Alive with disease
18/37 (49)
Deceased due to disease
8/37 (22)
Deceased due to other causes§
1/37 (3)
*Refused treatment, †Biologic/biologic response modifier drugs; sunitinib,
sorafenib, pazopanib, interferon, interleukin‑2, ‡Combination includes
radiation + surgery in 2/8, chemotherapy + biologic in 2/8, radiotherapy
+ biologic in 2/8, chemotherapy + radiotherapy + biologic in 1/8,
chemotherapy + radiosurgery in 1/8, §Dead from other causes (pulmonary
embolism). RCC: Renal cell carcinoma, OA: Ocular adnexal
214

Because OA metastases from RCC present in a setting of
advanced disease, systemic therapy plays an important role
and was employed in 57% of patients in this review. Biologic
therapy has become increasingly important in management
of RCC, evolving from nontargeted immune‑based therapies,
such as interferon‑alpha and interleukin‑2 in the 1990s[56] to
targeted therapies, such as receptor protein‑tyrosine kinase
inhibitors from 2006 and on, and immune checkpoint inhibitor
therapies in recent years.[63] This trend is also seen in our review
of reports from 2006, which documented the use of mammalian
target of rapamycin inhibitors, checkpoint inhibitors, and
receptor tyrosine kinase inhibitors.[43,48]

OA metastasis from RCC can occur as an initial manifestation
of RCC in 41% of patients. In patients with previously
diagnosed RCC, OA metastases tend to occur in a setting of
previously known metastatic disease on average 6–7 years
after diagnosis and as late as 15 years following diagnosis.
Advances in diagnostic modalities and targeted therapies
over the last 15 years have allowed significant improvement
in survival of patients with metastatic RCC, including those
with OA metastasis.
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